| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 8, 2024 | NBIX Neurocrine Biosciences Inc | Roberts Eiry49 | Chief Medical Officer | Sell | 2,101 | $138.49 | $290,968.09 | -4.5% | +3.4% | -8.8% | |
| Feb 8, 2024 | NBIX Neurocrine Biosciences Inc | Boyer David W.51 | Chief Corp. Affairs Officer | Sell | 1,784 | $137.09 | $244,563.90 | -8.0% | +3.4% | -8.8% | |
| Feb 8, 2024 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles55 | Chief Executive Officer | Sell | 5,314 | $138.74 | $737,270.71 | -0.5% | +3.4% | -8.8% | |
| Feb 8, 2024 | NBIX Neurocrine Biosciences Inc | Abernethy Matt57 | Chief Financial Officer | Sell | 2,260 | $138.73 | $313,529.61 | -3.6% | +3.4% | -8.8% | |
| Feb 8, 2024 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 1,952 | $138.47 | $270,284.02 | -2.5% | +3.4% | -8.8% | |
| Feb 8, 2024 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 2,580 | $139.16 | $359,041.22 | -1.0% | +3.4% | -8.8% | |
| Feb 7, 2024 | MRK Merck & Co., Inc. | Williams David Michael | EVP,Chief Info&Digital Officer | Sell | 1,451 | $127.57 | $185,108.28 | -6.8% | +2.9% | -29.0% | |
| Feb 2, 2024 | MRK Merck & Co., Inc. | Zachary Jennifer | EVP, General Counsel | Sell | 49,499 | $126.97 | $6,284,779.13 | -63.0% | +2.1% | -19.7% | |
| Feb 2, 2024 | MRK Merck & Co., Inc. | Mizell Steven52 | EVP, Chief Hr Officer | Sell | 50,694 | $126.65 | $6,420,349.48 | -68.2% | +2.1% | -19.7% | |
| Feb 2, 2024 | MRK Merck & Co., Inc. | Oosthuizen Johannes Jacobus | President, U.s. Market | Sell | 18,959 | $127.17 | $2,411,110.82 | -44.8% | +2.1% | -19.7% | |
| Feb 1, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 500 | $53.10 | $26,548.40 | -0.3% | -21.3% | -34.8% | |
| Feb 1, 2024 | TEVA Teva Pharmaceutical Industries Ltd | Weiss Amir | Chief Accounting Officer | Sell | 31,766 | $12.37 | $392,954.95 | -74.8% | +12.2% | +42.3% | |
| Feb 1, 2024 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 6,000 | $215.01 | $1,290,083.29 | -3.7% | +18.1% | +62.6% | |
| Feb 1, 2024 | NBIX Neurocrine Biosciences Inc | Delaet Ingrid67 | Chief Regulatory Officer | Sell | 1,045 | $140.65 | $146,975.39 | -7.3% | +0.4% | +6.6% | |
| Feb 1, 2024 | AKBA Akebia Therapeutics, Inc. | Butler John P.61 | CEO And President | Sell | 46,489 | $1.68 | $78,101.52 | -2.1% | -27.5% | +31.0% | |
| Feb 1, 2024 | AKBA Akebia Therapeutics, Inc. | Burke Steven Keith61 | SVP, Chief Medical Officer | Sell | 24,311 | $1.68 | $40,842.48 | -3.3% | -27.5% | +31.0% | |
| Jan 31, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 78,573 | $648.07 | $50,920,923.74 | - | +21.0% | +27.5% | |
| Jan 31, 2024 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 1,207 | $140.78 | $169,926.77 | -3.1% | -1.6% | +9.7% | |
| Jan 31, 2024 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 1,250 | $140.65 | $175,809.75 | -3.3% | -1.6% | +9.7% | |
| Jan 31, 2024 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 1,541 | $140.70 | $216,812.54 | -1.2% | -1.6% | +9.7% | |
| Jan 31, 2024 | NBIX Neurocrine Biosciences Inc | Boyer David W.51 | Chief Corp. Affairs Officer | Sell | 2,096 | $140.80 | $295,115.14 | -16.3% | -1.6% | +9.7% | |
| Jan 31, 2024 | NBIX Neurocrine Biosciences Inc | Abernethy Matt57 | Chief Financial Officer | Sell | 1,283 | $140.72 | $180,538.76 | -4.3% | -1.6% | +9.7% | |
| Jan 31, 2024 | NBIX Neurocrine Biosciences Inc | Cooke Julie59 | Chief Human Resources Officer | Sell | 1,740 | $141.29 | $245,841.50 | -4.7% | -1.6% | +9.7% | |
| Jan 31, 2024 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles55 | Chief Executive Officer | Sell | 2,707 | $140.69 | $380,844.58 | -0.5% | -1.6% | +9.7% | |
| Jan 31, 2024 | NBIX Neurocrine Biosciences Inc | Roberts Eiry49 | Chief Medical Officer | Sell | 1,457 | $140.79 | $205,131.90 | -6.5% | -1.6% | +9.7% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.